Bacterial and Fungal Co-Infections and Superinfections in a Cohort of COVID-19 Patients: Real-Life Data from an Italian Third Level Hospital.
COVID-19
bacterial
coinfections
community-acquired infection (CAI)
fungal
hospital-acquired infection (HAI)
superinfections
Journal
Infectious disease reports
ISSN: 2036-7430
Titre abrégé: Infect Dis Rep
Pays: Switzerland
ID NLM: 101537203
Informations de publication
Date de publication:
12 May 2022
12 May 2022
Historique:
received:
29
03
2022
revised:
07
05
2022
accepted:
09
05
2022
entrez:
1
6
2022
pubmed:
2
6
2022
medline:
2
6
2022
Statut:
epublish
Résumé
The use of immune suppressive drugs combined with the natural immune suppression caused by SARS-CoV-2 can lead to a surge of secondary bacterial and fungal infections. The aim of this study was to estimate the incidence of superinfections in hospitalized subjects with COVID-19. We carried out an observational retrospective single center cohort study. We enrolled patients admitted at the "Garibaldi" hospital for ≥72 h, with a confirmed diagnosis of COVID-19. All patients were routinely investigated for bacterial, viral, and fungal pathogens. A total of 589 adults with COVID-19 were included. A total of 88 infections were documented in different sites among 74 patients (12.6%). As for the etiology, 84 isolates were bacterial (95.5%), while only 4 were fungal (4.5%). A total of 51 episodes of hospital-acquired infections (HAI) were found in 43 patients, with a bacterial etiology in 47 cases (92.2%). Community-acquired infections (CAIs) are more frequently caused by
Identifiants
pubmed: 35645220
pii: idr14030041
doi: 10.3390/idr14030041
pmc: PMC9149992
doi:
Types de publication
Journal Article
Langues
eng
Pagination
372-382Références
Clin Infect Dis. 2021 Dec 6;73(11):e3606-e3614
pubmed: 32719848
J Clin Med. 2021 Oct 06;10(19):
pubmed: 34640612
Eur Rev Med Pharmacol Sci. 2019 Feb;23(3):1266-1278
pubmed: 30779096
Front Biosci (Landmark Ed). 2021 Sep 30;(9):405-408
pubmed: 34590454
Antibiotics (Basel). 2021 Sep 18;10(9):
pubmed: 34572709
PLoS Med. 2020 Dec 30;17(12):e1003501
pubmed: 33378357
J Chemother. 2021 Sep;33(5):302-318
pubmed: 33734040
Exp Gerontol. 2021 Oct 15;154:111507
pubmed: 34352287
Clin Microbiol Infect. 2021 Jan;27(1):83-88
pubmed: 32745596
Am J Emerg Med. 2022 Jan;51:1-5
pubmed: 34637995
Pharmacogenomics J. 2021 Jun;21(3):275-284
pubmed: 33542445
Antibiotics (Basel). 2021 Sep 17;10(9):
pubmed: 34572701
Int J Antimicrob Agents. 2020 May;55(5):105954
pubmed: 32234467
Arthritis Res Ther. 2019 Aug 2;21(1):183
pubmed: 31375130
Curr Pharmacol Rep. 2020;6(3):56-70
pubmed: 32395418
J Fungi (Basel). 2021 Sep 02;7(9):
pubmed: 34575758
Mycoses. 2021 Oct;64(10):1223-1229
pubmed: 34157166
J Oral Microbiol. 2021 Aug 26;13(1):1967699
pubmed: 34527182
Eur J Clin Microbiol Infect Dis. 2021 Nov;40(11):2323-2334
pubmed: 34155547
Rheumatology (Oxford). 2019 Feb 1;58(2):197-205
pubmed: 29618084
Lancet Child Adolesc Health. 2021 Jun;5(6):e19-e21
pubmed: 33961798
Eur Rev Med Pharmacol Sci. 2020 Jul;24(13):7534-7539
pubmed: 32706096
Ann Clin Microbiol Antimicrob. 2021 Sep 25;20(1):69
pubmed: 34563202
Infect Dis (Lond). 2022 Feb;54(2):134-144
pubmed: 34606393
Cells. 2020 May 20;9(5):
pubmed: 32443810
J Rheumatol Suppl. 2014 May;91:56-64
pubmed: 24789001
Laryngoscope. 2021 Jul;131(7):1626-1632
pubmed: 33491234
Rev Esp Quimioter. 2021 Sep;34 Suppl 1:69-71
pubmed: 34598432
New Microbes New Infect. 2021 Nov;44:100944
pubmed: 34567574
Sci Rep. 2021 Jun 17;11(1):12762
pubmed: 34140530
Biology (Basel). 2021 Aug 24;10(9):
pubmed: 34571699
J Clin Med. 2020 Mar 31;9(4):
pubmed: 32244365
Antibiotics (Basel). 2021 Sep 06;10(9):
pubmed: 34572662
SN Compr Clin Med. 2020;2(10):1777-1789
pubmed: 32904710
Antibiotics (Basel). 2021 Aug 24;10(9):
pubmed: 34572613
BMC Infect Dis. 2021 Sep 21;21(1):985
pubmed: 34548027